Feasibility Study of Metabolism Changes in Children, Teens, and Young Adults with Hodgkin or Non-Hodgkin Lymphoma Using Probe Medications

What this Trial Is About

Researchers are evaluating the acceptability and feasibility of studying phenoconversion, which is the change in metabolism phenotype, using probe medications in children, adolescents, and young adults aged 6 to 25 years diagnosed with Hodgkin lymphoma or non-Hodgkin lymphoma. This phase 1 study focuses on understanding how cancer and supportive care medicines metabolized by the CYP3A4, CYP2C19, and CYP2D6 pathways behave in this population. The findings will help guide more personalized precision medicine approaches in pediatric cancer treatment. Participants will receive sub-therapeutic doses of probe drugs, specifically omeprazole and dextromethorphan, administered orally or via nasogastric tube during scheduled hospital visits aligned with their lymphoma treatment. Blood samples will be collected at baseline and at longitudinal timepoints up to 24 months to measure the metabolism of these probe drugs and assess phenoconversion over time. During the study, participants will undergo blood draws and complete surveys assessing the acceptability of pharmacogenomic and phenoconversion testing. Researchers will monitor metabolic ratios, inflammatory markers, medication use, and adverse events related to probe drug administration. The study duration includes baseline and multiple follow-up assessments over 24 months to evaluate metabolism changes and feasibility of this approach in pediatric oncology patients.

A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.